© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Key insight from a panel of retinal disease specialists on the role of VEGF inhibitors in managing retinal diseases, including non-proliferative diabetic retinopathy.
November 8th 2021
Ehsan Rahimy, MD, and Diana V. Do, MD, explain the role of VEGF inhibitors in treating macular edema.
W. Lloyd Clark, MD, and Diana V. Do, MD, discuss their goals of treatment and the standard of care for macular edema.
November 15th 2021
Experts in retinal diseases provide insight into when to prescribe VEGF inhibitors and the initial conversations with patients about treatment.
Key opinion leaders review the efficacy and safety of available VEGF inhibitors for the treatment of macular edema and explain how effectiveness is evaluated.
November 22nd 2021
Expert ophthalmologists debate the rationale behind choosing an anti-VEGF inhibitor for patients and the challenges involved in treatment management.
Drs Ehsan Rahimy and Diana V. Do define diabetic retinopathy and describe the symptoms.
November 30th 2021
Joseph M. Coney, MD, and Ehsan Rahimy, MD, explain the complications of nonproliferative diabetic retinopathy and emphasize the importance of early detection.
Dr Joseph M. Coney provides insight into the goals of therapy for patients with nonproliferative diabetic retinopathy.
December 8th 2021
A panel of experts reviews data on nonproliferative diabetic retinopathy treatments from the PANORAMA, Protocol W, RISE, and RIDE studies.
Drs Ehsan Rahimy and Joseph M. Coney analyze the implications of clinical trial data on the management of nonproliferative diabetic retinopathy.
Psychological Resilience Linked to Better Physical Function in Older Adults with T2D
Incidence Rate of Adult ADHD Growing in Japan
Dapagliflozin Associated with Lower Risk of CV Death Across Ejection Fraction Spectrum